Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Bifidobacterium (mixed strains) has been investigated for its potential role in supporting gut health in individuals with Celiac Disease (CD). Although not a traditional treatment, there is emerging scientific interest in its use. Research has shown that patients with CD often have an altered gut microbiota composition, including reduced levels of Bifidobacteria, even after following a gluten-free diet. Several small-scale clinical studies and animal models suggest that supplementation with Bifidobacterium strains may help reduce intestinal inflammation, improve gut barrier function, and modulate immune responses in CD.

For example, a randomized controlled trial published in 2014 found that Bifidobacterium infantis supplementation reduced pro-inflammatory markers in children with CD on a gluten-free diet. Other studies have demonstrated that Bifidobacterium can help metabolize gluten peptides, potentially reducing their immunogenicity. However, these findings are preliminary and often limited by small sample sizes and short study durations.

Overall, while there is scientific rationale and some early clinical evidence supporting the potential benefit of Bifidobacterium supplementation in CD, the evidence remains limited and inconclusive. Larger, long-term trials are necessary to determine clinical efficacy and safety. Therefore, Bifidobacterium (mixed) use for Celiac Disease is justified by emerging scientific evidence, but the strength of evidence is modest (rated 2 out of 5).

More about Bifidobacterium (mixed)
More about Celiac Disease

Other ingredients used for Celiac Disease

Other health conditions supported by Bifidobacterium (mixed)

Products containing Bifidobacterium (mixed)